Venova Technologies Awarded $2.23M SBIR Phase II Grant From NIH For Novel Contraceptive Device
Summary
Venova Technologies received a $2.23 million SBIR Phase II grant from the NIH. The company will use the award to accelerate preclinical development of its hormone-free, copper-free cervical barrier contraceptive device. Venova says the funding brings its total capital raised to more than $5 million and supports its path to first-in-human clinical studies. The company targets women seeking more effective birth control options with fewer side effects.
Funding
Amount
$2.2M
Total raised
Date
July 25, 2025
Announcement date
Investors
-
Lead investors
Company
venovatechnologies.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected